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Breast cancer is the commonest form of cancer in women 
worldwide; there were an estimated 1.4 million cases 
world  wide in 2008 [1] and there is no part of the world 
where breast cancer is now a rare form of cancer [2]. In 
all major regions of the world, breast cancer is the 
commonest, or second commonest, cancer in women [3].
Focus on breast cancer up until now has almost entirely 
been on the situation in high-income, westernized, 
industrialised countries. However, there is a world out 
there outwith North America and Western Europe where 
cancer is a major and growing problem facing public 
health. With the growth and ageing of the world’s 
population, notable increases in life expectancy in people 
of lower-income levels in many countries and the 
increased tendency to adopt a westernised lifestyle, 
cancer is a rapidly growing global problem [4] and not 
one that the majority of the world is ready to cope with.
Of course, in the above statements, ‘cancer’ could be 
replaced by ‘vascular disease’ or ‘chronic obstructive 
pulmo  nary disease’ or ‘diabetes’ or any number of chronic 
conditions associated with ageing populations adopting a 
westernised lifestyle.
Today, there is no population around the world with a 
truly low risk of breast cancer and no woman in the world 
at a truly low risk of developing the disease. Th  e global 
burden of breast cancer doubled between 1975 and 2000. 
It seems certain to double again between now and 2030 
and the great majority of this burden will fall on low-
income and lower middle-income countries, where the 
resources to deal with the current situation, never mind 
future increases, are absent to a great degree.
Breast cancer in Africa
Th   e widespread belief that breast and other cancers are 
rare in low-income regions such as Africa is a myth. 
Akarolo-Anthony and colleagues [5] note that the 
probability that a woman who lives to age 65 in Kampala 
(Uga  nda) would develop a cancer is only 20% lower than 
that of her European contemporary. What diﬀ  ers 
markedly is the probability that the African woman will 
live to be 65 years of age compared to women in 
developed countries. Th  e concepts of risk and burden 
should be clearly diﬀ  erentiated and it should be noted 
that as life expectancy in Africa increases, so too will the 
cancer burden.
Akarolo-Anthony and colleagues [5] also note the 
increasing breast cancer rates occurring in Africa. Many 
factors could be associated with this increase but it 
appears attributable to a mixture of earlier age at 
menarche, women having fewer children and having their 
ﬁ  rst child at a later age, a reduction in the total time spent 
breast feeding, increased body mass index and a 
reduction in physical activity. Prospects for prevention 
through lifestyle alterations appear limited to increasing 
breast feeding, weight control and increasing levels of 
physical activity. Th  ere are proven chemoprevention 
approaches [6] but these have not been widely adopted 
even in high-resource countries.
In these lower-income settings, the case fatality rate is 
poor in comparison to high-resource countries. Women 
with breast cancer either present with large, advanced 
tumours or do not present until the disease is at an 
incurable stage. Of course, women still die from breast 
cancer in such countries without ever coming into 
contact with medical services. Th  e stigma associated 
with breast cancer in many countries is a major impedi-
ment to progress in controlling the disease and it should 
be a priority to reduce this stigma and eventually 
eliminate it entirely. Such stigma existed until recent 
decades even in countries such as the United States, but 
much work has been done to gradually overcome this 
phenomenon (see [7] for a clear description of this in the 
United States in the 1960s).
In lower-resource settings, treatment facilities, profes-
sional expertise and modern therapeutic technolo  gies 
frequently do not exist. Howell [8] has summarised some 
of the diﬃ     culties associated with introducing optimal 
treatment for breast cancer, as deﬁ  ned by standards in 
high-income countries, in the developing world, high-
lighted by the absence or low frequency of radiotherapy 
and systemic therapy services. In Africa, for example, a 
survey demonstrated that radiotherapy services were 
avail  able in only 17 of 44 countries surveyed [9]. Th  e 
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© 2010 BioMed Central Ltdintro  duction of radia  tion therapy suggest the cheaper and 
simpler cobalt machines compared with linear 
accelerators or shorter schedules [10]. Not only are cobalt 
machines cheaper, but they are practical given the 
absence of reliable electricity supplies in many lower 
resource settings.
Modern, curative treatments and treatment facilities 
are not generally available, and pain control, palliative, 
supportive and terminal care are notoriously absent. 
Th  ere are 29 countries identiﬁ   ed in Africa where the 
impor  tation of opioid drugs is prohibited, and in many 
others the dosage administered varies 100-fold [11]. 
Merriman [12] describes the situation on the ground in 
Africa and presents a viable model for improving this 
situation in an eﬀ  ective and inexpensive manner.
Breast cancer in India
In India, there are remarkable diﬀ  erences between the 
incidence rates of breast cancer in metropolitan, urban 
and rural areas. Using age-standardised incidence rates 
for the years 2006 to 2008, the recent provisional report 
of the National Cancer Incidence Programme (NCRP, 
unpublished data) provides reliable information on 
cancer incidence in many parts of India. In the greater 
metropolitan areas of Mumbai and Chennai, the breast 
cancer incidence rates are 33 and 32.1 per 100,000, 
respectively; in the urban areas of Pune and Bhopal, the 
incidence rates are lower at 24.4 and 25.5 per 100,000, 
respectively; and in the rural areas of Barshi and Barshi 
Town the rates are lower still at 7.7 and 15.0 per 100,000, 
respectively.
Th  e situation of breast cancer in India is, in a certain 
sense, fairly typical of the situation in many countries of 
Asia and other regions where dramatic economic and 
social change is taking place. Breast cancer is the second 
most common cancer among women in India and 
accounts for 7% of global burden of breast cancer and 
one-ﬁ   fth of all cancers among women in India. Over 
90,000 new cancer cases are estimated to occur this year 
and over 50,000 women are estimated to die of it annually 
in India [1]. It is the number one cancer among women in 
urban areas of India. Th  e incidence of breast cancer is 
approximately three times higher in urban areas 
compared to rural areas.
Figure 1. Globalissation of breast cancer. Average, annual age-standardised truncated (age 30 to 74 years) breast cancer incidence rates (1975 
onwards) in Mumbai and Chennai (India), China (Hong Kong and Shanghai), Colombia (Cali), Japan (Miyagi, Osaka, Yamagata), France (Bas Rhin, 
Calvados, Doubs, Isere, Somme, Tarn), Australia (New South Wales, South Australia, Victoria, Tasmania, Western Australia) and of whites and blacks 
in the United States Surveillance, Epidemiology and End Results (SEER) Program (Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San 
Francisco-Oakland, Seattle-Puget Sound, Utah).
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in India are still much lower than in high-resource 
countries (Figure 1). Given the myriad factors aﬀ  ecting 
the incidence of breast cancer, including the aging and 
growth of the Indian population and the increasing 
trends in breast cancer incidence, NS Murthy of the 
Indian Medical Research Council has estimated that the 
breast cancer burden in India will grow from 80,000 in 
2005, through 122,000 new cases in 2011, and attain a 
level of 141,000 cases by 2016 (R Badwe, personal 
communication).
India, typical of many countries undergoing rapid 
economic evolution, and a special case in many respects 
because of the large size of its population, requires 
investment in prevention, diagnosis and treatment. Th  ese 
include the widespread availability of reliable hormone 
receptor assessment, the availability of aﬀ  ordable drugs 
(for example, tamoxifen at US$1 per month and anthra-
cyclines at US$25 per cycle), cost-eﬀ  ective early detection 
models and programmes, low-cost intervention to 
improve outcome in spite late presentation, and eﬀ  ective 
population prevention inter  ventions, including increas-
ing breast feeding, reducing overweight and obesity and 
increasing physical activity.
Conclusions: do it rather than talk about it
One of the major barriers to progress in low-income and 
lower middle-income countries was the failure to men-
tion cancer and other chronic diseases in the Millennium 
Development Goals [4]. Signed and approved by most of 
the heads of state or government at the United Nations, 
these ten points were designed to help the 1 billion 
poorest people on the planet. Governments and health 
departments strive to accomplish these goals and one 
consequence is the lower priority currently aﬀ  orded to 
chronic disease in some of the world’s poorest countries.
Th  e growing epidemic of breast cancer in lower 
resource settings presents a major challenge to global 
public health, especially given the failure to cope with the 
current situation. Th   is epidemic is here and now 
confronting the cancer control community and will 
assuredly become worse.
What can be done about this? Th  e  ﬁ  rst and crucial step 
must be to turn this question from the passive to the 
active voice. What can we do about this? Not your neigh-
bour, not your cancer organisation or the cancer 
organisation in another country, nor some international 
association. Responsibility cannot be shifted onto the 
shoulders of others. Th   e cancer control community needs 
to take more responsibility. Too often too diﬀ  use to be 
eﬀ  ective, this community needs to gain focus and acquire 
strong leadership. Th  e time for committees, meetings, 
reports and declarations is over and the need for real and 
eﬀ  ective action is a call that must not be ignored.
Currently, a clearer picture of the global issues of 
cancer is emerging and clear priority targets can be 
identiﬁ   ed. Individually, we must get involved, and 
collectively, we can make a diﬀ  erence.
Th  ere is an urgent need to enact eﬀ  ective  cancer 
control policies in many parts of the world and the 
urgency is emphasised by the rapid changes taking place 
in cancer risk and cancer burden, particularly in lower 
and middle income countries. Breast cancer, being such a 
common form of the disease, is a good model for what 
can be done and what should be done. Two examples 
illustrate key elements of what is needed. Th  e Breast 
Health Global Initiative [13] seeks to improve diagnosis, 
treatment and outcome through a highly successful, 
hands-on programme of scientiﬁ  c and clinical activities. 
Th  e Susan G Komen Global Alliance, building on the 
great success of Susan G Komen for the Cure, is 
spearheading a coalition whose aim is to take active steps 
to reduce the breast cancer burden, and that of other 
cancers, among women living in poor regions of the 
world. Th  e Alliance serves as a platform for innovative 
partnerships to provide screening and treatment to low-
resource, under-served global populations and also as an 
organizing platform to bring together various 
organizations to design, fund and implement health 
programs that include screening and/or treatment for 
breast and cervical cancer.
Benjamin Disraeli and William Gladstone were two 
legendary British politicians and political rivals in the late 
1800s. In Parliament, Disraeli was requested to 
diﬀ  erentiate a tragedy and a calamity. He responded that 
if Mr Gladstone was to fall in the Th   ames, then that could 
be described as a tragedy. If someone was to pull him out, 
then that would be a calamity.
Th  e impact of the current and future global cancer 
burden can be described as a tragedy. If we fail to do 
anything about this evolving epidemic, then that would 
be a calamity.
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